Literature DB >> 810076

Pipemidic acid, a new antibacterial agent active against Pseudomonas aeruginosa: in vitro properties.

M Shimizu, Y Takase, S Nakamura, H Katae, A Minami.   

Abstract

Pipemidic acid, 8-ethyl-5,8-dihydro-5-oxo-2-(1-piperazinyl)-pyrido [2,3-d]pyrimidine-6-carboxylic acid, is a new derivative of piromidic acid. It is active against gram-negative bacteria including Pseudomonas aeruginosa as well as some gram-positive bacteria. Its potency is generally greater than that of piromidic acid and nalidixic acid. Cross-resistance is not observed between pipemidic acid and various antibiotics, and most of bacteria resistant to piromidic acid and nalidixic acid are moderately susceptible to pipemidic acid. The activity of pipemidic acid is scarcely affected by the addition of serum, sodium cholate, or change of medium pH, but is subject to the influence of inoculum size. Its action is bactericidal above minimal inhibitory concentrations.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 810076      PMCID: PMC429279          DOI: 10.1128/AAC.8.2.132

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  3 in total

1.  1,8-NAPHTHYRIDINE DERIVATIVES. A NEW CLASS OF CHEMOTHERAPEUTIC AGENTS.

Authors:  G Y LESHER; E J FROELICH; M D GRUETT; J H BAILEY; R P BRUNDAGE
Journal:  J Med Pharm Chem       Date:  1962-09

2.  Pipemidic acid: absorption, distribution, and excretion.

Authors:  M Shimizu; S Nakamura; Y Takase; N Kurobe
Journal:  Antimicrob Agents Chemother       Date:  1975-04       Impact factor: 5.191

3.  Pyrido(2,3-d)pyrimidine antibacterial agents. 3. 8-Alkyl- and 8-vinyl-5,8-dihydro-5-oxo-2-(1-piperazinyl)pyrido(2,3-d)pyrimidine-6-carboxylic acids and their derivatives.

Authors:  J Matsumoto; S Minami
Journal:  J Med Chem       Date:  1975-01       Impact factor: 7.446

  3 in total
  24 in total

1.  In vitro and in vivo activity of NY-198, a new difluorinated quinolone.

Authors:  T Hirose; E Okezaki; H Kato; Y Ito; M Inoue; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1987-06       Impact factor: 5.191

2.  Inhibition of conjugal transfer of R plasmids by pipemidic acid and related compounds.

Authors:  S Nakamura; S Inoue; M Shimizu; S Iyobe; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1976-11       Impact factor: 5.191

3.  New nalidixic acid resistance mutations related to deoxyribonucleic acid gyrase activity.

Authors:  J Yamagishi; Y Furutani; S Inoue; T Ohue; S Nakamura; M Shimizu
Journal:  J Bacteriol       Date:  1981-11       Impact factor: 3.490

4.  Single- and multiple-dose pharmacokinetics of pipemidic acid in normal human volunteers.

Authors:  E Klinge; P T Männistö; R Mäntylä; J Mattila; U Hänninen
Journal:  Antimicrob Agents Chemother       Date:  1984-07       Impact factor: 5.191

5.  Nalidixic acid-resistant mutations of the gyrB gene of Escherichia coli.

Authors:  J Yamagishi; H Yoshida; M Yamayoshi; S Nakamura
Journal:  Mol Gen Genet       Date:  1986-09

6.  In vitro and in vivo antibacterial activities of KB-5246, a new tetracyclic quinolone.

Authors:  Y Kotera; S Mitsuhashi
Journal:  Antimicrob Agents Chemother       Date:  1989-11       Impact factor: 5.191

7.  In vitro antibacterial properties of AT-2266, a new pyridonecarboxylic acid.

Authors:  S Nakamura; A Minami; H Katae; S Inoue; J Yamagishi; Y Takase; M Shimizu
Journal:  Antimicrob Agents Chemother       Date:  1983-05       Impact factor: 5.191

8.  Mode of incomplete cross-resistance among pipemidic, piromidic, and nalidixic acids.

Authors:  S Inoue; T Ohue; J Yamagishi; S Nakamura; M Shimizu
Journal:  Antimicrob Agents Chemother       Date:  1978-08       Impact factor: 5.191

9.  The in vitro and in vivo activity of ciprofloxacin.

Authors:  H J Zeiler; K Grohe
Journal:  Eur J Clin Microbiol       Date:  1984-08       Impact factor: 3.267

10.  Resistance of Pseudomonas aeruginosa PAO to nalidixic acid and low levels of beta-lactam antibiotics: mapping of chromosomal genes.

Authors:  M Rella; D Haas
Journal:  Antimicrob Agents Chemother       Date:  1982-08       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.